



Annual General Meeting held in OssDsign AB

On 9 June 2026, OssDsign AB (publ) held its annual general meeting for 2026. Below is a summary of the resolutions passed at the annual general meeting (complete information and documents regarding the decisions of the meeting are available on the company's website www.ossdesign.com).

The annual general meeting resolved:

- to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2025;
- that the company's result shall be carried forward in new account and that no dividend shall be paid for the financial year 2025;
- to grant the board members and the CEO discharge from liability for the financial year 2025;
- that the board of directors shall consist of five ordinary members without deputy members, to re-elect Christer Fåhraeus, Jill Schiaparelli, David Jern and Tomas Blomquist as ordinary board members, election of Per Aniansson as new ordinary board member, and to elect Per Aniansson as new chairman of the board;
- that a registered accounting firm shall be elected as auditor and to re-elect Ernst & Young AB as the company's auditor;
- that fees payable to the board members until the end of the next annual general meeting shall amount to a total of SEK 1,300,000 out of which SEK 400,000 shall be paid to the chairman and SEK 300,000 to each of the other board members except for Christer Fåhraeus to whom no board fee is to be paid. In addition, it was resolved that fees shall be paid to the board members serving on the audit committee for the period until the end of the next annual general meeting in a total amount of SEK 120,000, of which SEK 80,000 shall be paid to the chairman of the audit committee and SEK 40,000 to the other member of the audit committee;
- that the auditor is to be paid in accordance with approved invoices;
- on an authorization for the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures through which the company's share capital may be increased by an amount corresponding to not more than twelve (12) per cent of the share capital after such issue(s);
- to adopt the board's proposed resolution on (i) implementation of a long-term incentive program for employees and contractors (Warrant Programme 2026/2029:1) through a directed issue of no more than 3,100,000 warrants of series 2026/2029:1 to the company and/or any of its subsidiaries and approval of the subsequent transfer of the issued warrants to certain employees and contractors within the group against payment of the market value of the option right or, provided that it does not entail negative tax consequences for the group, free-of-charge, and (ii) cancellation of Warrant Programme 2025/2028:1 which has not been utilised. Each warrant entitles the holder to subscribe for one (1) new share in the company, as adjusted downwards by application of the mandatory so-called quotient exercise model set forth in the proposed resolution, during the period from and including 1 July 2029 until and including 31 December 2029, against payment of a subscription price per new share corresponding to 160 percent of the volume weighted average trading price for the company's share on Nasdaq First North Growth Market during a period of five (5) trading days before the annual general meeting. The warrants are governed by customary terms and conditions, including any adjustments to the subscription price and the number of new shares that each warrant entitles the holder to subscribe for in the event of certain events affecting the company.

For further information, please contact:

Mark Waugh, CEO
+1 (260) 804-1342
mark.waugh@ossdesign.com

Certified Adviser

The Company's Certified Adviser is DNB Carnegie Investment Bank AB (publ)

About OssDsign

OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. The company has a strong presence in the U.S. market. OssDsign's share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.